Premium
Mobilization of predominantly Philadelphia chromosome‐negative blood progenitors using cyclophosphamide and rHUG‐CSF in early chronic‐phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control
Author(s) -
Hughes T. P.,
Grigg A.,
Szer J.,
Ho J.,
Ma D.,
Dale B. M.,
Green R. M.,
Norman J. E.,
Sage R. E.,
Herrmann R.,
Cannell P.,
Schwarer A. P.,
Taylor K.,
Atkinson K.,
Arthur C.
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.d01-2068.x
Subject(s) - medicine , regimen , cyclophosphamide , gastroenterology , mobilization , immunology , chemotherapy , archaeology , history
Mobilization of Philadelphia chromosome (Ph) negative blood progenitors was attempted in 23 newly diagnosed chronic myeloid leukaemia (CML) patients using a regimen of cyclophosphamide (CY) 5 g/m 2 and rHUG‐CSF 150 μg/m 2 daily. This regimen was well tolerated with no major adverse events reported. More than 2 × 10 6 /kg CD34 + cells were collected in 21 patients (91%). Predominantly Ph‐negative mobilization (0–25% Ph‐positive) was seen in 30% of cases overall and was confined to patients with a Sokal prognostic score < 1 (7/11 with Sokal score <1; 0/12 with Sokal score ≥1). Within the low Sokal index group, a low WBC count pre‐mobilization and a low WBC nadir both correlated strongly with Ph‐negative mobilization ( P =0.006 and 0.02 respectively). Five of 19 patients receiving at least 6 months of Roferon A therapy post mobilization achieved a major cytogenetic response; all five patients were Ph‐negative mobilizers. Therefore CML patients can be divided into a good‐prognosis group in whom predominantly Ph‐negative progenitors can be mobilized using a regimen of moderate intensity if haematological control is achieved pre‐mobilization, and a poor‐prognosis group for whom predominantly Ph‐positive cells are mobilized with this regimen regardless of haematological control.